AM218, a new polyanionic polysaccharide, induces radioprotection in mice when administered shortly before irradiation

• Published in: International journal of radiation biology Vol. 71; no. 1; p. 101
• Main Authors: Güenechea, G, Albella, B, Bueren, J A, Maganto, G, Tuduri, P, Guerrero, A, Pivel, J P, Real, A
• Format: Journal Article
• Language: English
• Published: England 01.01.1997
• Subjects: Animals; Blood Cells - radiation effects; Drug Administration Schedule; Hematopoietic Stem Cells - radiation effects; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Polysaccharides - pharmacology; Radiation-Protective Agents - pharmacology; Survival Rate
• ISSN: 0955-3002
• DOI: 10.1080/095530097144472

We have shown that the polyanionic polysaccharide AM218 improves the survival rate of the potentially lethally irradiated mice. This radioprotective effect was highly dependent on the administration schedule, the most efficient protocol being that in which the drug was given shortly before irradiation. The haematopoietic implications in the pharmacological action of AM218 were confirmed by the improved recovery in the three peripheral blood lineages observed in the AM218-treated mice. However, because of a marked increase observed in the number of white blood cells during the period of highest mortality of the control irradiated mice, effects on the neutrophil lineage may account for the effects mediated by AM218 in the irradiated mice. Both in vitro and in vivo treatment with AM218 before irradiation improved the survival rate of CFU-GM progenitors, while no effects were observed on the CFU-S pool. This led us to postulate that the improved survival rate of the committed progenitors, at least the granulocyte-macrophage progenitors, accounts for the radioprotective capacity of AM218.